Hip Replacement Clinical Trials

Clinical trials related to Hip Replacement Procedure

Comparison of Safety Profile and Efficacy of Different Doses of Intrathecal Morphine in Total Hip Replacement.

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug, Device, Procedure
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

Pain management after total hip replacement is one of the most important aspects of postoperative care for patients and clinicians alike. One of the most common techniques used in anesthesia for this procedure is spinal anesthesia with concurrent administration of opioids into spinal sac. Addition of opioids not only prolongs the anesthesia but also provides pain relief after the procedure for a limited amount of time. Because of its unique chemical properties morphine provides the longest pain relief amongst currently known opioids lasting up to 24 hours. Unfortunately this beneficial effect is associated with both minor and serious adverse effects, most important of which is respiratory depression. To limit this potenitialy fatal adverse effect dosing of morphine must be very precise in order to balance advantages and risks. The aim of the study was to assess effectiveness and safety profile of different doses of morphine administered during spinal anesthesia for pain control.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Informed consent to participate in trial

• Qualification for total hip replacement surgery

• ASA physical status I-III

• BMI 19-30

• Lack of contraindications for drugs and interventions used in trial

Locations
Other Locations
Poland
Zespół Opieki Zdrowotnej w Końskich
RECRUITING
Gmina Końskie
Wojewódzki Szpital Specjalistyczny nr 5 im. św. Barbary
RECRUITING
Sosnowiec
Uniwersytecki Szpital Kliniczny nr 1 im. prof. Tadeusza Sokołowskiego PUM w Szczecinie
NOT_YET_RECRUITING
Szczecin
Contact Information
Primary
Szymon Białka, MD PhD
szymon.bialka@gmail.com
+48323407593
Backup
Jakub Żak, MD
jakubzak.sum@gmail.com
+48607936667
Time Frame
Start Date: 2025-03-04
Estimated Completion Date: 2026-06-28
Participants
Target number of participants: 120
Treatments
Active_comparator: M50
In addition to bupivacaine patients received 50 mcg morphine sulphate intrathecaly.
Active_comparator: M100
In addition to bupivacaine patients received 100 mcg morphine sulphate intrathecaly.
Active_comparator: M150
In addition to bupivacaine patients received 150 mcg morphine sulphate intrathecaly.
Related Therapeutic Areas
Sponsors
Leads: Medical University of Silesia

This content was sourced from clinicaltrials.gov